He doesn't believe in bullish news on Potash (POT) and he is not a buyer of the stock. VIVUS, Inc. (NASDAQ: VVUS) is another stock Cramer analyzed in his show at a request of a viewer. He thinks this company is an event driven and the …
VVUS) prior to the July 15 th panel review date of the company’s new weight-loss drug. The stock is currently in the 10 dollar range for common shares, and it stands to rise substantially if the panel review is positive. A positive panel review …
Stock market news today is dominated by Microsoft, Nokia, Verizon, and the rest of these stocks, reports and mergers you have to stay on top of ...
However, given the uncertainty of this issue, investors are likely to remain on the sidelines and focus on the drug's launch ramp before bidding up the stock. Expect VVUS shares to lift slightly today on the news that Qsymia is the first of a …
MOUNTAIN VIEW, Calif. and NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) ("VIVUS" or "the Company"), a pharmaceutical company commercializing and developing innovative, next-generation therapies to …
Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
Shares of Vivus Inc. (NASDAQ: VVUS) are higher on the session by 4.10%, currently trading at $9.90. The stock has been trading lower over the past month, but has held a much longer-term uptrend dating back to March of 2009. Options …